Show simple item record

dc.contributor.authorWeir, Matthew R
dc.contributor.authorChen, Yen-Wen
dc.contributor.authorHe, Jinghua
dc.contributor.authorBookhart, Brahim
dc.contributor.authorCampbell, Alicia
dc.contributor.authorAshton, Veronica
dc.date.accessioned2021-09-22T19:07:17Z
dc.date.available2021-09-22T19:07:17Z
dc.date.issued2021-09-04
dc.identifier.urihttp://hdl.handle.net/10713/16692
dc.description.abstractAims: To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods: Patients aged ≥18 years were identified from a healthcare claims database with the following criteria: newly initiating rivaroxaban or warfarin, ≥1 medical claim with a diagnosis of AF, obesity determined by validated machine learning algorithm, and ≥1 claim with a diagnosis of diabetes or for antidiabetic medication. Treatment cohorts were matched using propensity scores and were compared for stroke/systemic embolism (SE) and major bleeding using Cox proportional hazards models. Results: A total of 9999 matched pairs of NVAF patients with obesity and diabetes who initiated treatment with rivaroxaban or warfarin were included. The composite risk of stroke/SE was significantly lower in the rivaroxaban cohort compared with the warfarin cohort (HR 0.82; 95% CI 0.74-0.90). Risks of ischemic and hemorrhagic strokes were also significantly reduced with rivaroxaban versus warfarin, but not SE. Major bleeding risk was similar between treatment cohorts (HR 0.92; 95% CI 0.78-1.09). Conclusions: In NVAF patients with comorbidities of obesity and diabetes, rivaroxaban was associated with lower risks of stroke/SE and similar risk of major bleeding versus warfarin.en_US
dc.description.urihttps://doi.org/10.1016/j.jdiacomp.2021.108029en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofJournal of Diabetes and Its Complicationsen_US
dc.rightsCopyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.en_US
dc.subjectAnticoagulationen_US
dc.subjectDiabetes mellitusen_US
dc.subjectNonvalvular atrial fibrillationen_US
dc.subjectObesityen_US
dc.subjectRivaroxabanen_US
dc.subjectWarfarinen_US
dc.titleEffectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetesen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jdiacomp.2021.108029
dc.identifier.pmid34538715
dc.source.beginpage108029
dc.source.endpage
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record